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METHODS AND PHARMACEUTICAL 
COMPOSITIONS FOR DECORPORATION OF 
RADIOACTIVE COMPOUNDS 
This application claims the bene?t of US. provisional 
patent application Ser. No. 60/983,401 ?led on 29 Oct. 2007. 
This invention Was made With at least partial Government 
support under National Institutes of Health Award No. 
HHSN266200500045C. The Government may have certain 
rights in this invention. 
TECHNICAL FIELD 
The present invention relates generally to chelating agents 
and to related methods for utilizing those chelating agents in 
pharmaceutical compositions to decorporate or remove tran 
suranic or other radioactive elements and compounds, from 
mammals such as humans. 
BACKGROUND OF THE INVENTION 
The calcium and Zinc salts of diethylenetriamine penta 
acetate (Ca-DTPA and Zn-DTPA) have been approved by the 
Food and Drug Administration for the decoporation, removal 
or elimination of knoWn or suspected internal contamination 
of humans With the transuranic metals (Z>92), plutonium, 
americium and curium. More speci?cally Ca-DTPA and Zn 
DTPA are chelating agents that Work by binding and holding 
onto radioactive materials or certain other poisons that enter 
the body. Once bound to the radioactive material or poison, 
the chelating agent is then passed from the body in the urine 
and or feces. The chelating agents help decrease the amount 
of time it takes to get the poison out of the body. 
Ca-DTPA and Zn-DTPA are not absorbed from the GI tract 
to any appreciable extent and therefore must be administered 
by (l) subcutaneous injection directly into a vein, (2) intra 
venously by dripping into a vein from a bag or (3) by nebu 
liZed inhalation by means of a mist or spray breathed into the 
lungs. 
A need exists for the development of a form of diethylene 
triamine penta-acetic acid (DTPA) that can be administered 
orally for use in the possible event of a massive radiation 
poisoning emergency such as could occur by the detonation 
of a dirty bomb by terrorists or inadvertent release of radio 
activity into a Work place or the environment. The present 
invention relates to pharmaceutical compositions and treat 
ment methods meeting this need. More speci?cally, esters 
and amides of DTPA have been developed that are readily 
absorbed folloWing oral administration and are subsequently 
and rapidly hydrolyZed back to active DTPA by esterases or 
amidases normally present in the intestinal lumen, liver and/ 
or blood. 
SUMMARY OF THE INVENTION 
In accordance With the purposes of the present invention as 
described herein, a method is provided for treating a mammal 
to remove systemic transuranic or other radioactive elements 
and compounds. The method is broadly described as com 
prising the step of administrating to the mammal a pharma 
ceutically effective amount of a decorporation agent having a 
chemical formula 
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Where RihORl or iNHRz; 
Rl:same or different and is independently selected from 
H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl 
and at least one R1 is not hydrogen; and 
R2:same or different and is independently selected from 
Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe 
nylalanine ethyl ester. 
More speci?cally describing the invention, the method 
includes administering preferably betWeen about 5 and about 
250 milligrams of decorporation agent per kilogram of the 
total Weight of the mammal per day. More preferably, the dose 
is betWeen 5 to 100 milligrams/kg body Weight, and most 
preferably the dose is between 15 to 45 milligrams/kg body 
Weight. 
The method may further include administering the decor 
poration agent for an extended period of time such as over 
days and Weeks in order to achieve medically su?icient deco 
rporation. 
In accordance With an additional aspect of the present 
invention a method is provided for treating a mammal to 
remove radioactive elements and compounds comprising the 
step of administering to the mammal a pharmaceutically 
effective amount of a pharmaceutical composition including 
a pharmaceutical carrier and a decorporation agent having a 
chemical formula 
0 
Where RihORl or iNHRz; 
Rl:same or different and is independently selected from 
H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl 
and at least one R1 is not hydrogen; and 
R2:same or different and is independently selected from 
Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe 
nylalanine ethyl ester. 
The pharmaceutical composition may further include an 
antioxidant, a preservative and/or a binder, a viscosity 
enhancing agent, and a sWeetening agent as desired depend 
ing upon the form of the product (eg. liquid dosage forms and 
solid dosage forms such as poWder, pill, tablet, capsule, gel 
cap for oral administration). 
In accordance With yet another aspect of the present inven 
tion a composition is provided for removing systemic radio 
active compounds from a mammal. The composition com 
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prises a pharmaceutical carrier and a pharmaceutically 
effective amount of a decorporation agent having a chemical 
formula 
0 O 
O HLR R)“ O RJ\/N\/\N/\/N\)kR 
R of 
Where R*\ORl or iNHRZ; 
RIIsame or different and is independently selected from 
H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl 
and at least one R1 is not hydrogen; and 
R2:same or different and is independently selected from 
Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe 
nylalanine ethyl ester. 
For oral administration, the carrier may be a solution com 
prised of a mixture of solvents including, but not limited to, 
Water, ethanol, propylene glycol, glycerin, comoil, ethyl ole 
ate, glycofurol, mineral oil, peanut oil, polyethylene glycol, 
propylene glycol, sesame oil, soybean oil, or triacetin. The 
viscosity of the vehicle can also be increased With any number 
of agents including, but not limited to, acacia, alcohols, alg 
inic acid, carbomer, carboxymethylcellulose, ethylcellulose, 
povidone, or xanthum gum. The pH of the vehicle can also be 
adjusted to a pH that best stabiliZes the decorporation agent. 
The preferred pH is in the range of pH 2-8 While the pH range 
of 3-7.5 is more preferred, and the pH range of 3.5 to 7 is most 
preferred. pH adjusting agents include, but are not limited to, 
citric acid/citrate, phosphoric acid/phosphate, or boric acid/ 
borate. 
The composition for an oral solution includes betWeen 
about 50 and about 98 Weight percent pharmaceutical carrier 
With the decorporation agent in the pharmaceutical carrier at 
a concentration ranging from 5 to 250 mg/mL, and more 
preferably at a concentration ranging from 50 to 150 mg/mL. 
The composition may further include betWeen 0.001 and 
about 3 Weight percent antioxidant. The antioxidant may be 
selected from a group consisting of ascorbic acid, its salts and 
esters; fumaric acid, its salts and esters; malic acid, its salt and 
esters; alpha-tocopherol, its salts and esters; sodium met 
abisulphite, sodium bisul?te; butylated hydroxyanisole 
(BHA); butylated hydroxytoluene (BHT); gallic acid, its salts 
and esters; EDTA. It is Well knoWn that other compounds not 
listed can have antioxidant properties and these compounds 
are not intentionally omitted herein. 
The composition may further include betWeen about 0.001 
and about 10 Weight percent preservative. That preservative 
may be selected from a group consisting of methylparaben, 
ethylparaben, propylparaben, butylparaben, benZoic acid, 
sodium benZoate, benZyl alcohol, sorbic acid and potassium 
sorbate, EDTA, glycerol, phenol, thimerosol, phenoxyetha 
nol, and cresol. It is Well knoWn that other compounds not 
listed can have preservative properties and these compounds 
are not intentionally omitted herein. 
Further the composition may include betWeen about 0.01 
and about 25 Weight percent binder. The binder may be 
selected from a group consisting of microcrystalline cellu 
lose, silicon dioxide, dibasic calcium phosphate, starch, glu 
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cose, gelatin, acacia, sucrose, dextrin, guar gum, hydroxy 
ethyl cellulose, polymethacrylates, maltodextrin, povidone, 
Zein, methyl cellulose, and sodium alginate. It is Well knoWn 
that other compounds not listed can serve as binders and these 
compounds are not intentionally omitted herein. 
Further the composition may include the mixture of the 
liquid, semi-liquid or crystalline decorporation agent With an 
additive in order to aid in the preparation of an acceptable 
pharmaceutical composition. For example, a liquid or semi 
liquid decorporation agent may be added to a dry and porous 
pharmaceutical excipient such as colloidal silicon dioxide 
that absorbs the liquid in order to impart ?oW properties 
similar to the pharmaceutical excipient. Other examples of 
excipient include, but are not limited to, bentonite, cellulose, 
kaolin, and magnesium aluminum silicate. As another 
example, a crystalline decorporation agent may be added to 
dry pharmaceutical excipient to disperse the agent and 
improve ?oW. Examples of such excipients include, but are 
not limited to, lactose, mannitol, maltodextrin, and silicon 
dioxide. 
Further the composition may include betWeen about 0.01 
and about 30 Weight percent disintegrant. The disintegrant 
may be selected from a group consisting of alginic acid, 
crospovidone, croscarmellose sodium, soy polysaccharides, 
cellulose, magnesium aluminum silicate, povidone, sodium 
starch glycolate and sodium carboxymethyl starch. It is Well 
knoWn that other compounds not listed can have disintegrant 
properties and these compounds are not intentionally omitted 
herein. 
In the folloWing description there is shoWn and described 
preferred embodiments of the invention, simply by Way of 
illustration of some of the modes best suited to carry out the 
invention. As it Will be realiZed, the invention is capable of 
other different embodiments and its several details are 
capable of modi?cation in various, obvious aspects all With 
out departing from the invention. Accordingly, the draWings 
and descriptions Will be regarded as illustrative in nature and 
not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 graphically illustrates the bio-availability of 5 mg of 
DTPA administered to rats intravenously; and 
FIG. 2 graphically illustrates the bioavailability of an 
equivalent molar dose of decorporation agent of the present 
invention orally administered to a rat in a 10% ethanol solu 
tion. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS OF THE INVENTION 
A composition for removing radioactive elements and 
compounds, such as transuranic compounds, from a mam 
mal, such as a human, comprises a pharmaceutical carrier and 
a pharmaceutically effective amount of a decorporation agent 
having a chemical formula 
O O 
O %R R)“ O RAK/NWN/VNQkR 
R 
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Where R*\ORl or iNHRZ; 
RIIsame or different and is independently selected from 
H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl 
and at least one R1 is not hydrogen; and 
R2Isame or different and is independently selected from 
Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe 
nylalanine ethyl ester. 
The phrase “pharmaceutical carrier” as used herein means 
a pharmaceutically-acceptable material, composition or 
vehicle, such as a liquid or solid ?ller, diluent, excipient, 
solvent or encapsulating material, involved in carrying and 
transporting an active agent, in this case the decorporation 
agent, from one organ or portion of a subjects body to another 
organ, or portion of the subjects body. Some examples of 
materials that can serve as pharmaceutical carriers include: 
poWdered cellulose, calcium carbonate, lactose, starch, poly 
lactic acid, polyglycolic acid, phospholipids, mannitol, cal 
cium sulfate, sorbitol, dicalcium phosphate, kaolin, sodium 
chloride, poWdered sugar and microcrystalline cellulose. 
The phrase “pharmaceutically effective amount” as used 
herein means that amount of decorporation agent Which is 
effective for removing systemic transuranic compounds from 
a mammal or for producing some other desired therapeutic 
effect in a mammal in accordance With a reasonable bene?t/ 
risk ratio applicable to any medical treatment. 
The phrase “medically su?icient decorporation” relates to 
the administration of the decorporation agent to a mammal to 
result in detectable elimination of the radioactive element 
and/ or compound from the mammal in the urine, feces, other 
bodily ?uids and exhaled gas from the lungs. It is appreciated 
by those in the ?eld that the transuranic compounds are very 
poisonous and radiotoxic in the body. A decorporation agent 
that When administered over time removes detectable amount 
of the transuranic compound from the body Will generally 
improve the medical condition of the mammal. Thus, it is 
envisioned that dosing of the decorporation agent should 
continue until the transuranic compound is no longer detect 
able by the various modes of elimination from the body. 
Antioxidants useful in the present invention include but are 
not limited to ascorbic acid, its salts and esters; fumaric acid, 
its salts and esters; malic acid, its salt and esters; alpha 
tocopherol, its salts and esters; sodium metabisulphite, 
sodium bisul?te; butylated hydroxyanisole (BHA); butylated 
hydroxytoluene (BHT); gallic acid, its salts and esters; 
EDTA. 
Preservatives useful in the present invention include but are 
not limited to methylparaben, ethylparaben, propylparaben, 
butylparaben, benZoic acid, sodium benZoate, benZyl alcohol, 
sorbic acid and potassium sorbate, EDTA, glycerol, phenol, 
thimerosol, phenoxyethanol, and cresol. 
Binders useful in the present invention include but are not 
limited to microcrystalline cellulose, dibasic calcium phos 
phate, starch, glucose, gelatin, acacia, sucrose, dextrin, guar 
gum, hydroxyethyl cellulose, polymethacrylates, maltodex 
trin, povidone, Zein, methyl cellulose, and sodium alginate. 
Possible formulations include those suitable for oral, sub 
lingual, buccal, nasal, pulmonary, rectal, and topical admin 
istration. Most suitable means for administration for a par 
ticular patient Will depend on the nature and severity of the 
transuranic poisoning, the length of time betWeen the poison 
ing and the discovery of the poisoning and, obviously, the age 
and condition of the patient. 
Formulations suitable for oral administration may be pro 
vided as discreet units, such as tablets, capsules, cheWing 
gum, loZenges or the like, Which containing a predetermined 
amount of the decorporation agent: as poWders or granules, as 
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solutions or suspensions in aqueous or non-aqueous liquids, 
or as oil-in-Water or Water-in-oil emulsions, or as micelles, 
nanoparticles, liposomes, or microparticles. For example, the 
formulation may include a viscosity-enhancing agent such as 
beesWax, other Waxes, polymer, glycerolmonooleate, leci 
thin, PEG 400 Monostearate, hydroxy propyl cellulose, 
hydroxy propyl methyl cellulose, polyethylene glycol 8000 
(PEG 8000), PEG 3350, methyl cellulose, 2-propenoic acid 
(Carbopol 934P), polysorbate 20 (TWeen 20), polysorbate 80 
(TWeen 80) and alpha-Tocopheryl polyethylene glycol 1000 
succinate (TPGS) and mixtures thereof. The formulation is 
heated and then ?lled into hard gelatin capsules. Upon cool 
ing, the capsules Would contain a semi-solid material that 
included the decorporation agent. 
Formulations suitable for sub-lingual or bucal administra 
tion include loZenges, rapidly dissolving tablets, thin-?lms, 
lollipops comprising the decorporation agent and, typically a 
?avored base, such as sugar and acacia or tragacanth in pas 
tilles comprising the active compound in an inert base, such as 
gelatin and glycerin or sucrose acacia. 
Formulations particularly useful for pediatric administra 
tion include oil solutions and self-emulsifying drug delivery 
systems. A simple oil-based solution contains dissolved 
decorporation agent. Various oils may be utiliZed including 
pharmaceutical grade vegetable oils such as (l) long-chain 
triglycerides such as corn oil, cottonseed oil, sesame oil and 
soybean oil and (2) medium-chain triglycerides such as min 
eral oil. 
Self-emulsifying drug delivery systems are mixtures of 
oils, surfactants and solvents that can improve the oral 
absorption of highly lipophilic compounds. They can be for 
mulated as microemulsion pre-concentrates that Will sponta 
neously self-emulsify upon ingestion after dilution by the 
aqueous ?uids of the GI tract. Unlike a non-emulsion formu 
lation that relies on endogenous surfactants (i.e. bile salts) for 
emulsi?cation, self-emulsifying drug delivery systems con 
tain exogenous surfactants to self-promote micelle forma 
tion. The emulsi?cation increases the surface area of the 
solubiliZed phase of the drug, thereby increasing absorption 
potential. 
Formulations of the invention may be prepared by any 
suitable method, typically by uniformly and intimately 
admixing the decorporation agent and carrier in the required 
proportions and then, if necessary shaping the resulting mix 
ture into the desired shape. For example, a tablet may be 
prepared by compressing an intimate mixture comprising a 
poWder or granules of the decorporation agent and one or 
more optional ingredients such as a binder, lubricant, inert 
dilutant or surface active dispersing agent, or by molding an 
intimate mixture of poWdered decorporation agent and inert 
liquid dilutant. In addition, a solution or suspension of the 
decorporation agent may be ?lled into a solid dose form such 
as a hard-gelatin capsule or soft-gelatin capsule. 
In addition to the ingredients mentioned above, formula 
tions to the present invention may include other additives 
knoWn to those skilled in the art of pharmacy to be useful for 
their intended purpose. For example, formulations suitable 
for oral administration may include ?avoring agents. 
The method of treating a mammal to remove radioactive 
elements or compounds such as systemic transuramic com 
pounds may be broadly described as comprising administer 
ing to the mammal a pharmaceutically effective amount of a 
decorporation agent having a chemical formula 
US 8,030,358 B2 
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O O 
O %R R)% O RAK/NWN/VNQkR 
R f 
Where R*\ORl or iNHRZ; 
RIIsame or different and is independently selected from 
H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl 
and at least one R1 is not hydrogen; and 
R2:same or different and is independently selected from 
Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe 
nylalanine ethyl ester. 
Alternatively, the method may be described as comprising 
administrating to the mammal a pharmaceutically effective 
dosage amount of a pharmaceutical composition including a 
pharmaceutical excipient and a decorporation agent having a 
chemical formula 
0 o 
o %R 11% o Rk/N\/\N/\/N\)i\R 
R 
0 
Where R*\ORl or iNHRZ; 
RIIsame or different and is independently selected from 
H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or benZyl 
and at least one R1 is not hydrogen; and 
R2:same or different and is independently selected from 
Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or phe 
nylalanine ethyl ester. Either oral or nasal administration may 
be utiliZed. 
The method includes administering betWeen about 5 and 
about 250 milligrams and more typically betWeen about 15 
and about 45 milligrams of decorporation, agent per kilogram 
of the mammal’s total body Weight per day. Further the 
method includes administering the decorporation agent for at 
least one day and, if needed, over an extended period of time 
such as over days and Weeks. 
The folloWing synthesis and examples are presented to 
further illustrate the invention, but it is not to be considered as 
limited thereto. The nomenclature system for the substituted 
DTPA compounds is as folloWs: 
Abbreviation Compound 
C2E5 ethyl ester, penta-substituted 
Cl2E5 lauryl ester, penta-substituted 
C18E5 stearyl ester, penta-substituted 
CbMZyIES benzyl ester, penta-substituted 
CPhmA5 amide of phenylalanine ethyl 
ester, penta-substituted 
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Prodrug Synthesis 
Target molecules preparation summary: DTPA esters may 
be prepared using DTPA as a starting material. The starting 
material diethylenetriaminepentaacetic acid, (DTPT, 1) could 
be smoothly converted to the pentaethyl ester 2, (C2E5) in 
high yield by re?uxing the pentaacid in ethanol acidi?ed With 
HCl gas, aqueous HCl, sulfuric acid, etc, etc. Removal of the 
solvent yielded the hydrochloride salt of: 
OR 
RO N OR 
j‘/\N/\/ \/\N/\’( 
o KH/OR ROW‘) 0 
O O 
2. R : Ethyl 
as a glassy, hygroscopic solid. We also prepared the free base 
as a clear, colorless oil by Washing With an aqueous sodium 
carbonate solution, drying the organic layer With sodium 
sulfate and removal of the volatiles. The corresponding Cl8 
pentaester: 
O O 
R I octadecyl 
Was prepared by heating DTPA in toluene in an excess of 
l-pentadecanol in the presence of sulfuric acid With aZeotro 
pic removal of Water. Column chromatography to remove the 
excess alcohol provided the above compound as a Waxy solid. 
We prepared the C 12 pentaester: 
O 
OC12H25 
C12H25O N OC12H25 
WNA/ \/\NW 
0 ocuH25 o 
OC12H25 
O O 
by a different route. Dodecylbromo acetate Was prepared 
cleanly from l-dodecanol and bromo acetyl bromide. The 
bromoacetate Was reacted With diethylenetriamine to yield, 
after column chromatography, the C12E5 as an orange oil. 
US 8,030,358 B2 
9 10 
DTPA DerivatiZation diethylenetriamine to produce the requisite pentaester Which 
Was puri?ed by column chromatography. 
_ _ The triester series Was approached by ?rst reacting dieth 
Attennon Was next turned to the PreParanOn of DTPA ylenetriamine With ethyl tri?uoroacetate in dichloromethane 
esters by the alternate Pathway Shown 1n Scheme 2~ The 5 to produce the ditri?uoroacetamide 9 in good yield. Further 
Carbon Skeleton Of DTPA Can be prepared by reaction of reaction With 3 equivalents of ethyl bromoacetate and a base 
bromoacetic acid derivatives. The pentadodecyl ester C12E5 provided the triethyl ester 10, and using 1 equivalent of ethyl 
Was prepared by reaction of dodecylbromoacetate 7 With bromoacetate, the monoester ll. 
O O 
OH OH 
HO N OH A020, Py HO N O 
N/\/ \/\N/X —DiOXan6 , N/\/ \/\N 
70 deg C. 
o o O 8 hr 0 o 
O 
OH OH O O 
1 4 
EtOH 
HCl 
O 
2. R I Ethyl 5 
3. R I octadecyl 
O 
O OC12H25 
N BIQK C12H25 c H o N 00 H 
H2N/\/ \/\NH2 + / —> 12 25 WNA/ \/\N 12 25 
o oclzH25 o 
OC12H25 
6 7 O 8 O 
O O O 
O O 
H 
i /\/N\/\ Br OEt o OEt iPrZNEt o OEt 0 
F3C H H 0P3 N H N\/\ /\ N L 
a F3C N/\/ N C133 F3C C133 
EtO OEt 
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EXPERIMENTAL EXAMPLES 
DTPA Pentaethyl Ester (C2E5), 2 
DTPA (5 g, 12.7 mmol) Was suspended in anhydrous abso 
lute ethanol (200 mL) that had been saturated With anhydrous 
HCl. The reaction Was stirred at re?ux overnight under an 
Argon atmosphere. Approximately 20 mL of ethanol Was 
distilled, and the reaction kept at re?ux a further 24 h. The 
volatiles Were removed in vacuo and a glassy, hygroscopic 
solid Was obtained in quantitative yield (7.2 g). To prepare the 
free base, the material Was dissolved in dichloromethane and 
Washed With 5% aqueous potassium carbonate, dried With 
NaZSO4 and concentrated in vacuo to yield a clear, colorless 
oil. Mass spectrum (M+1) El, 534. lH-NMR (CDCl3) 4.16 (q, 
1:7 HZ, 10H); 3.58, (s, 8H), 3.48, (s, 2H), 2.86-2.80 (complex 
multiplet, 8H), 1.27 (t, 1:7 HZ, 12H), 1.26 (t 1:7 HZ, 3H). 
DTPA Penta Cl8 Ester (C18E5), 2 
DTPA (5.0 g, 12.7 mmol) Was suspended in toluene and 3 
mL concentrated sulfuric acid added. Octadecyl alcohol (31 
g, 114 mmol) Was added and the reaction ?tted With a Dean 
Stark apparatus. The reaction Was re?uxed overnight Where 
upon the volatiles removed. The crude material Was dissolved 
in dichloromethane and separated by column chromatogra 
phy (silica gel) eluting With dichloromethane and then 20% 
methanol in dichloromethane to yield 2 (15.2 g) as an off 
White Waxy solid. 
DTPA Bis-Anhydride, 3. 
DTPA (50 g, 0.13 mol) Was added to freshly distilled acetic 
anhydride (80 mL) and anhydrous pyridine (80 mL) and 
anhydrous dioxane (50 mL), and heated to 70° C. under anAr 
atmosphere for 7 h. The reaction Was cooled, ?ltered, and the 
solid dried under high vacuum at 50° C. to yield the bis 
anhydride 3 (35 g) as an off-White poWder. Mp 183-186. 
lH-NMR (DMSO-d6) 13.5 (bs, 1H), 3.66 (s, 2H), 3.45 (s, 
8H), 3.07 (t, 1:60 HZ, 4H), 2.92 (t, 1:60 HZ, 4H). 
Pentadodecyl Ester of DTPA (C12E5), 8. 
To a solution of 1-dodecanol (25.0 g, 0.134 mol) in dichlo 
romethane (150 mL), triethylamine (21.0 mL, 0.150 mol) and 
dimethylaminopyridine (0.5 g) Was added a solution of bro 
moacetyl bromide (27.6 g, 0.137 mol) in dichloromethane (50 
mL) at 5° C. dropWise. The mixture Was stirred to room 
temperature overnight. The mixture Was ?ltered, Washed With 
brine and dried over MgSO4 and the volatiles removed. The 
product dodecyl ester Was used Without further puri?cation. 
Diethylenetriamine (2.52 g, 0.0244 mol) Was dissolved in 
anhydrous acetonitrile (250 mL) and diisopropylethylamine 
(21.1 g, 0.742 mol) added. A solution of bromoester 7 (50.0 g, 
0.163 mol) in acetonitrile (100 mL) Was added sloWly keep 
ing the internal temperature beloW 15° C. The reaction Was 
then alloWed to stir to room temperature overnight. The vola 
tiles Were removed and the residue dissolved in ethyl acetate 
and Washed With saturated sodium bicarbonate, dried over 
NaZSO4 and the solvent removed to an orange oil. Chroma 
tography on silica gel (5% methanol-chloroform) yielded an 
orange oil. MS (MALDI), 1235 (M+1). 
Ditri?uoroacetamide 9. 
A solution of diethylenetriamine (20.0 g, 0.194 mol) in 
dichloromethane (500 mL) Was cooled to 0° C. and ethyltri 
?uoroacetate added dropWise. The reaction Was stirred to 
room temperature overnight and then the solvent and volatiles 
removed in vacuo to provide a White solid. MS (El) 296 
(M+1). 
Triethyl ester (C2E3), 10. 
The above ditri?uoroacetamide 9 (55 g, 0.186 mol) Was 
dissolved in anhydrous DMF (200 mL) and added sloWly at 
0° C. to a solution ofNaH (15.6 g, 0.650 mol) in DMF (200 
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mL). The reaction Was alloWed to stir 2 h then bromoethylac 
etate (99.0 g, 0.595 mol) added, and the reaction Warmed to 
room temperature overnight. The reaction Was diluted With 
aqueous sodium bicarbonate, and extracted With ethyl 
acetate, Which Was back extracted With brine. The organic 
layer Was dried, and the volatiles removed to produce an oily 
glass. MS (MALDI) 554 (M+1). 
Monoethyl Ester 11. 
The di-tri?uoroacetamide 9 (55 g, 0.186 mol) Was dis 
solved in anhydrous acetonitrile (300 mL), and diisopropyl 
ethylamine (28.9 g, 0.223 mol) added. Ethylbromoacetate 
(37.4 g, 0.223 mol) Was added dropWise to the solution and 
then it Was stirred overnight at room temperature. The reac 
tion Was diluted With aqueous sodium bicarbonate, and 
extracted With ethyl acetate, Which Was back extracted With 
brine. The organic layer Was dried, and the volatiles removed 
to produce an oily glass. MS (MALDI) 382 (M+1). 
Prodrug Synthesis 
Various esters of DTPA Were prepared from diethylenetri 
amine, 6. The primary amines could be selectively protected 
as the di-tri?uoroacetamide by reaction With ethyl tri?uoro 
acetate to produce 9 in good yield. Reaction of 9 With 3 
equivalents of ethylbromoacetate and NaH produced the tri 
ester 10. Reaction of 9 With 1 equivalent of ethylbromoacetate 
produced the monoester 11. 
o OEt o 
i N i F3C N/\/ \/\N c1:3 —> 
EtO OEt 
0 
l0 
0 
OEt 
/\/ N\/\ HN NH —> 
EtO k'fOEt 
O 0 
l2 
0 
OEt 
N 
HOZC N/\/ \/\N/\CO2H 
EtO OEt 
O O 
14 
O 
O OEt O 
A N —’ 
F C \/\ g C133 
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N 
HZN /\/ \/\ NH2 
13 
O 
OEt 
Tri?uoroacetamides of the type 9 derived from diethylen 
etriamine are known to be hydrolyzed in the presence of alkyl 
esters, such as benzyl or tert-butyl esters With hydrazine. 
Alternatively, the compounds may be hydrolyzed using lim 
iting KOH at reduced temperatures. Other possible routes to 
the diamino esters derived from 10 and 11 include replacing 
the tri?uoroacetamide group With a benzyl urethane Which 
can be de-protected non-hydrolytically. 
The tri?uoroacetamide groups are removed from 10 and l l 
to produce the mono-ethyl and the tri-ethylacetate esters of 
diethylenetriamine, l2 and 13. Compounds 12 and 13 my be 
alkylated. The C 12 and C 18 analogs of 12 and 13 are prepared 
by the analogous routes. From these, C12El, C12E3, Cl 8E1, 
and C18E3 are prepared. 
In yet another alternative scheme the tri?uoroacetamides 
l0, 1 1 may be hydrolyzed using a limiting amount of hydrox 
ide at reduced temperatures. 
Preparation of the Pentabenzylester 8 and the Pentaamide 
9 
O 
HLOH 
)1 /\/N\/\ OH N N 
O HO w 
0 
H‘OR 
)1 /\/N OR N N 
O 
2 R I ethyl 
3 R I dodecyl 
4 R I octadecyl 
8 R I benzyl 
OH 
HO 
OR 
R0 
or 0 
v 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
14 
-continued 
5 R I ethyl 
6 R I dodecyl 
7 R I octadecyl 
HL 
O o 
130% Ph 
NH2 
R I Phenylalanine Ethyl ester 
The pentabenzyl ester 8, C benZyZE5 Was prepared as the free 
base. The viscous oil Was readily prepared and puri?ed by 
column chromatography in multi-gram scale. The pentaa 
mide 9, based upon the natural enantiomer of phenylalanine, 
Was prepared from phenylalanine ethyl ester in good yield as 
a White poWder. 
Prodrug Synthesis 
Chemical Synthesis 
TWo neW prodrugs Were synthesized and puri?ed. The 
chemical characterization of these compounds con?rmed 
their structure. 
The synthesis of the l4C-labeled analog of one of these 
prodrugs, C2E5, Was completed and its radiochemical purity 
Was con?rmed. A portion of the product Was de-esteri?ed to 
yield l4C-DTPA. Both l4C-C2E5 and l4C-DTPA Were used 
in an animal study. 
Schematic of Reaction PathWay for: 
DTPA Triethyl Ester. 
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Using similar technology, the penta-dodecyl DTPA ester 
has been prepared. 
H 
OC12H25 
C12H25O O O OC12H25 
f O N 
N /\/ \/\ N 
CIZHZSOWH k'(oclzn25 
O O 
6 
Oral Solution Formulations as Examples of Pharrnaceuti 
cal Compositions 
TWo oral solution formulations Were developed. The ?rst 
formulation Was alcohol free While the second formulation 
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contained a 10% ethanol to maximize the solubility of the 
decorporation agent. The composition of the oral solution 
formulations is as folloWs: 
C2E5 Oral Solution Formulation 1 
Ingredient Concentration Function 
C2E5 base 75 mgmL Active 
Citric acid 2.10% W/v Buffer/Solubilizing agent 
Methyl paraben 0.18% W/v Preservative (Ideal for the pH 
range 4-8) 
Propyl paraben 0.02% W/v Preservative (Ideal for the pH 
range 4-8) 
Propylene glycol 3.00% W/v Cosolvent, Preservative aid 
Sorbitol 10.00% W/v SWeetening agent 
Disodium EDTA 0.10% W/v Anti-oxidant 
Puri?ed Water q.s. to 100 mL Vehicle 
C2E5 Oral Solution Formulation 2 
Ingredient Concentration Function 
C2E5 base 75 mgmL Active 
Citric acid 2.10% W/v Buffer/Solubilizing agent 
Methyl paraben 0.18% W/v Preservative (Ideal for the pH 
range 4-8) 
Propyl paraben 0.02% W/v Preservative (Ideal for the pH 
range 4-8) 
Propylene glycol 3.00% W/v Cosolvent, Preservative aid 
Sorbitol 10.00% W/v SWeetening agent 
Disodium EDTA 0.10% W/v Anti-oxidant 
Ethanol 10.0% W/v Co-solvent 
Puri?ed Water q.s. to 100 mL Vehicle 
Bioavailability Study 
A bioavailability study Was conducted in Which ?ve rats 
Were intravenously administered 5 mg of DTPA and another 
5 rats Were orally administered an equivalent loWer dose 
(approximately 7 mg) of C2E5 in a 10% ethanol solution. 
Blood samples Were obtained at regular intervals from an 
in-dWelling catheter that had been surgically implanted prior 
to the administration of the doses. The pharmacokinetic 
analysis of the data is presented in FIGS. 1 and 2. 
The data indicates that the bioavailability of C2E5 is essen 
tially 100% in the rat model. Since no C2E5 can be detected 
in the plasma, it appears that once C2E5 is absorbed from the 
gastrointestinal tract it is quantitatively and rapidly converted 
to DTPA. As expected the blood concentration pro?le results 
in loWer blood levels and a longer duration compared to IV 
DTPA. 
Small Animal Decorporation Ef?cacy Study 
Studies in small groups of animals have demonstrated that 
the decorporation of 241Am folloWing oral administration of 
C2E5 to rats compared favorably to decorporation folloWing 
IV administration of equivalent doses of DTPA. 
The invention has been described herein With regard to 
certain preferred pharmaceutical composition embodiments 
and treatment methods. HoWever, as obvious variations 
thereon become apparent to those skilled in the art, the inven 
tion is not to be considered as limited thereto. 
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What is claimed: 
1. A method of treating a mammal to remove a radioactive 
element or compound, comprising: 
administering to said mammal a pharmaceutically effec 
tive amount of a decorporation agent having a chemical 5 
formula: 
O O 
o %R R)“ o 
)k/Nw /\/ NQk R N R 
O 
Where RihORl or iNHRZ; 
RIIsame or different and is independently selected from 
H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or ben 
Zyl and at least one R1 is not hydrogen; and 
RZIsame or different and is independently selected from 
Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or 
phenylalanine ethyl ester. 
2. The method of claim 1, including using oral administra 
tion. 
3. The method of claim 1, including administering betWeen 
about 5 and about 250 milligrams of decorporation agent per 
kilogram of said mammal’s total body Weight per day. 
4. The method of claim 3, including administering said 
decorporation agent for at least an extended period of time 
such as over days and Weeks in order to achieve medically 
suf?cient decorporation. 
5. A method of treating a mammal to remove a radioactive 
element or compound, comprising: 
administering to said mammal a pharmaceutically effec 
tive amount of a pharmaceutical composition including 
a pharmaceutical carrier and a decorporation agent hav 
ing a chemical formula: 
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Where RihORl or iNHRZ; 
RIIsame or different and is independently selected from 
H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or ben 
Zyl and at least one R1 is not hydrogen; and 
RZIsame or different and is independently selected from 
Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or 
phenylalanine ethyl ester. 
6. The method of claim 5, Wherein said pharmaceutical 
composition also includes an antioxidant. 
7. The method of claim 5, Wherein said pharmaceutical 
composition also includes a preservative. 
60 
65 
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8. The method of claim 5, Wherein said pharmaceutical 
composition also includes a binder. 
9. The method of claim 5, including using oral administra 
tion. 
10. The method of claim 5 including administering 
betWeen about 15 and about 45 milligrams of decorporation 
agent per kilogram of said mammal’s total body Weight per 
day. 
11. The method of claim 5, including administering said 
decorporation agent for at least an extended period of time 
such as over days and Weeks in order to achieve medically 
suf?cient decorporation. 
12. A composition for removing a radioactive element or 
compound from a mammal, comprising: 
a pharmaceutical carrier; and 
a pharmaceutically effective amount of a decorporation 
agent having a chemical formula: 
O O 
O HLR RAIW O RJK/NWN/VNQkR 
R 
0 
Where R*\ORl or iNHRZ; 
RIIsame or different and is independently selected from 
H, Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl or ben 
Zyl and at least one R1 is not hydrogen; and 
R2:same or different and is independently selected from 
Cl-C3O alkyl, C2-C3O alkenyl, C2-C3O alkynyl, benZyl or 
phenylalanine ethyl ester. 
13. The composition of claim 12, including betWeen about 
50 Weight percent and about 98 Weight percent carrier and the 
decorporation agent in the carrier at a concentration ranging 
from 5 to 250 mg/mL. 
14. The composition of claim 13 further including betWeen 
about 0.001 and about 3 Weight percent anti-oxidant. 
15. The composition of claim 14, Wherein said anti-oxidant 
is selected from a group consisting of ascorbic acid, its salts 
and esters; fumaric acid, its salts and esters; malic acid, its salt 
and esters; alpha-tocopherol, its salts and esters; sodium met 
abisulphite, sodium bisul?te; butylated hydroxyanisole 
(BHA); butylated hydroxytoluene (BHT); gallic acid, its salts 
and esters; EDTA. 
16. The composition of claim 13, further including 
betWeen about 0.001 and about 10 Weight percent preserva 
tive. 
17. The composition of claim 16, Wherein said preservative 
is selected from a group consisting of methylparaben, eth 
ylparaben, propylparaben, butylparaben, benZoic acid, 
sodium benZoate, benZyl alcohol, sorbic acid and potassium 
sorbate, EDTA, glycerol, phenol, thimerosol, phenoxyetha 
nol, and cresol. 
18. The composition of claim 13, further including 
betWeen about 0.01 and about 25 Weight percent binder. 
19. The composition of claim 18, Wherein said binder is 
selected from a group consisting of microcrystalline cellu 
lose, silicon dioxide, dibasic calcium phosphate, starch, glu 
cose, gelatin, acacia, sucrose, dextrin, guar gum, hydroxy 
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ethyl cellulose, polymethacrylates, maltodextrin, povidone, 
Zein, methyl cellulose, and sodium alginate. 
20. The composition of claim 13, further including 
between about 0.0001 and about 5.0 Weight percent Viscosity 
enhancer. 
21. The composition of claim 20, Wherein said Viscosity 
enhancer is selected from a group consisting of beesWaX, 
other Waxes, polymer, glycerolmonooleate, lecithin, PEG 
20 
400 Monostearate, hydroxy propyl cellulose, hydroxy propyl 
methyl cellulose, polyethylene glycol 8000 (PEG 8000), PEG 
3350, methyl cellulose, 2-propenoic acid (Carbopol 934P), 
polysorbate (TWeen 20), polysorbate 80 (TWeen 80) and 
alpha-Tocopheryl polyethylene glycol 1000 succinate 
(TPGS) and mixtures thereof. 
* * * * * 
